Blood Pressure Assessment in Atrial Fibrillation
Evaluation of the Oscillometric Blood Pressure Measurement in Atrial Fibrillation and Relation of Blood Pressure With Serum Biomarkers and Echocardiographic Indexes
1 other identifier
observational
100
1 country
1
Brief Summary
This is a cross-sectional study including patients with permanent atrial fibrillation. Assessment will include:
- clinic blood pressure measurements (mercury sphygmomanometer and automated oscillometric device)
- 24-hour ambulatory blood pressure monitoring
- determination of various serum markers and cardiac ultrasound.
- evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2010
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2010
CompletedFirst Submitted
Initial submission to the registry
March 16, 2010
CompletedFirst Posted
Study publicly available on registry
March 17, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedSeptember 14, 2017
September 1, 2017
7.8 years
March 16, 2010
September 13, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Blood Pressure Measurement in Atrial Fibrillation,Serum Markers and echocardiographic indexes in atrial fibrillation (AF)
1. Evaluation of the oscillometric technique of an electronic device in blood pressure measurement. 2. Evaluation of the relationship of blood pressure levels with serum markers and ultrasonographic cardiac indexes. 3. Evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG
Baseline
Study Arms (2)
AF
Hypertensive patients in AF
Non-AF
Hypertensive Patients
Eligibility Criteria
SUBJECTS REFERRED TO HYPERTENSION CENTER
You may qualify if:
- Hypertensives adults in atrial fibrillation
You may not qualify if:
- Renal disease (Cr \> 2 mg/l).
- Patients with pacemaker rhythm during the study.
- Each patient with acute disease (inflammation, surgery), malignancy, collagen diseases, pulmonary fibrosis, renal failure, liver failure, chronic inflammatory diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hypertension Center, Third Internal Medicine Dpt, University of Athens
Athens, Greece
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
George S Stergiou, MD
Hypertension Center,Third Department of Medicine,University of Athens,Greece
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor of Medicine and Hypertension
Study Record Dates
First Submitted
March 16, 2010
First Posted
March 17, 2010
Study Start
March 1, 2010
Primary Completion
December 1, 2017
Study Completion
December 1, 2017
Last Updated
September 14, 2017
Record last verified: 2017-09